Skip to main content
main-content

Latest news

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Hybrid immune cell could contribute to type 1 diabetes autoimmunity

Lymphocyte

Researchers have discovered an immune cell with the attributes of both B cells and T cells, which is present in increased frequency in some people with type 1 diabetes and capable of activating insulin-specific T-helper cells.

Maternal education has major impact on glycemic control in children

Mother and child with diabetes

Researchers report that women’s educational attainment is strongly associated with the glycated hemoglobin levels of their children with type 1 diabetes.

Latest headlines

06-14-2019 | Diabetes prevention | News

Teplizumab, low-dose ATG hold greatest type 1 diabetes immunotherapy promise

Of the immunotherapies tested to date, teplizumab and low-dose antithymocyte globulin are the most promising for slowing the decline in C-peptide in people with newly diagnosed type 1 diabetes, researchers report.

06-13-2019 | Dapagliflozin | ADA 2019 | News

Dapagliflozin renoprotective in diabetes patients with preserved kidney function

Detailed analysis of renal outcomes in the DECLARE-TIMI 58 trial confirms that treatment with the sodium-glucose cotransporter 2 inhibitor dapagliflozin is renoprotective in patients with type 2 diabetes and preserved kidney function.

06-12-2019 | Canagliflozin | ADA 2019 | News

Canagliflozin benefits span multiple cardiovascular backgrounds

Canagliflozin reduces the risk for major cardiovascular events and kidney failure versus placebo in patients with type 2 diabetes and chronic kidney disease with and without a known history of cardiovascular disease, CREDENCE study data show.

Features and expert interviews

04-24-2019 | Type 2 diabetes | Feature | Article

Young-onset type 2 diabetes: A different process?

Escalating obesity prevalence and severity has led to type 2 diabetes being diagnosed in ever-younger people, including children. medwireNews rounds up the accumulating evidence suggesting a particularly severe diabetes course in these young people.

04-17-2019 | Nephropathy | Podcast | Article

Nephrologist expert commentary: The CREDENCE trial

Consultant nephrologist Andrew Frankel tells medwireNews about the rationale and key findings of the CREDENCE trial, and discusses the potential benefits of SGLT2 inhibitors beyond type 2 diabetes (9:45).

04-17-2019 | Nephropathy | Podcast | Article

Primary care expert commentary: The CREDENCE trial

General practitioner Kevin Fernando talks to medwireNews about the importance of the CREDENCE trial from a primary care perspective (4:43).

Image Credits